Therapy-induced tumour senescence drives oxaliplatin resistance via ADORA1–dependent palmitic acid metabolic reprogramming in colorectal cancer

Yuqin Long, Xue Li, Yunxi Zhu, Yang Shen, Xiaotian Zhou, Ziqin Wei, Yin Yue, Jie Zhang, Changhong Miao
Oncogene · Springer Nature · 2026-11-03 · DOI: 10.1038/s41388-026-04024-z

Abstract

Oncogene, Published online: 03 November 2026; doi:10.1038/s41388-026-04024-z Early resistance to oxaliplatin-based neoadjuvant chemotherapy (NACT) remains a major obstacle to improving outcomes for patients with locally advanced colorectal cancer (CRC). We found that even brief exposure to oxaliplatin drives therapy-induced senescence (TIS) in CRC tumours. Eliminating these senescent cells reduced oxaliplatin resistance in both resistant CRC cells and xenograft models. By integrating transcriptomic and lipidomic analyses with molecular and functional studies, we identified adenosine A1 receptor (ADORA1) as a key regulator of TIS and oxaliplatin resistance. Mechanistically, ADORA1 stabilises

Read at publisher →

Similar articles